NasdaqGM:OCULPharmaceuticals
Will Ocular Therapeutix’s (OCUL) AXPAXLI Data Spotlight Redefine Its Retinal Competitive Positioning?
Ocular Therapeutix recently announced that it will present additional data and analyses from its Phase 3 SOL-1 superiority trial of AXPAXLI for wet age-related macular degeneration at multiple scientific conferences in April 2026, highlighting durability, efficacy, and safety outcomes.
These upcoming scientific presentations are set to put AXPAXLI’s clinical profile under closer scrutiny from physicians and researchers, potentially sharpening how the therapy is perceived within the...